Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial

Fig. 1

Study Design. a. Duloxetine initiated at 30 mg QD dose. At Weeks 1–7, the dose could be increased to 60 mg QD based on investigator’s clinical judgement. If subsequent dose decrease to 30 mg QD was needed, it could not be increased again during the double-blind period. b. From Week 2 to 13, patients randomized to placebo or duloxetine 30 mg who discontinued prior to entering the open-label extension treatment period received placebo in the drug taper period. c. From Week 14 to 33, dose increases were permitted at scheduled visits (to a maximum dose of 60 mg QD) and dose decreases were permitted at scheduled or unscheduled visits (to a minimum dose of 30 mg QD) based on investigator’s clinical judgement. d. Patients on duloxetine 60 mg QD dose were tapered to 30 mg QD, and those who were on 30 mg QD during open label treatment period were not required to enter the drug taper period

Back to article page